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Nearly all adults harbor acute myeloid leukemia (AML)-related clonalhematopoietic mutations at a variant allele fraction (VAF) of≥0.0001, yet relatively few develop hematologic malignancies. We
conducted a nested analysis in the Nurses’ Health Study and Health
Professionals Follow-Up Study blood subcohorts, with up to 22 years of fol-
low up to investigate associations of clonal mutations of ≥0.0001 allele fre-
quency with future risk of AML. We identified 35 cases with AML that had
pre-diagnosis peripheral blood samples and matched two controls without
history of cancer per case by sex, age, and ethnicity. We conducted blinded
error-corrected sequencing on all study samples and assessed variant-asso-
ciated risk using conditional logistic regression. We detected AML-associat-
ed mutations in 97% of all participants (598 mutations, 5.8/person).
Individuals with mutations ≥0.01 variant allele fraction had a significantly
increased AML risk (OR 5.4, 95%CI: 1.8-16.6), as did individuals with high-
er-frequency clones and those with DNMT3A R882H/C mutations. The
risk of lower-frequency clones was less clear. In the 11 case-control sets
with samples banked ten years apart, clonal mutations rarely expanded
over time. Our findings are consistent with published evidence that detec-
tion of clonal mutations ≥0.01 VAF identifies individuals at increased risk
for AML. Further study of larger populations, mutations co-occurring with-
in the same pre-leukemic clone and other risk factors (lifestyle, epigenetics,
etc.), are still needed to fully elucidate the risk conferred by low-frequency
clonal hematopoiesis in asymptomatic adults. 
Introduction
Clonal hematopoiesis of indeterminate potential (CHIP) has been defined as
somatic mutations in the peripheral blood at variant allele fractions (VAF) >0.02 in
individuals without evidence of hematologic malignancy.1 The threshold of 0.02
VAF was arbitrarily derived, reflecting the technical limitations of the standard next
generation sequencing (NGS) and not biological risk of leukemic transformation
with lower frequency mutations. To date, there have been no systematic screening
recommendations for identifying or surveilling CHIP in healthy individuals.
Nonetheless, the presence of CHIP has been shown to increase the risk of develop-
ing hematologic malignancy (in aggregate) by 0.5-1% per year,2,3 although the
absolute risk of leukemic transformation in individuals with CHIP is very low.
Recently, two studies demonstrated an increased risk of developing AML in indi-
viduals with CHIP detected using targeted sequencing of peripheral blood samples
collected several years prior to diagnosis.4,5
Independently, error-corrected sequencing (ECS) has enabled accurate interroga-
tion of the hematologic somatic mutational profile at VAF ≥0.00016 and demon-
strated that selection of pre-existing clones can lead to therapy-related leukemia.7
Our ECS-based study of blood samples collected approximately ten years apart
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ABSTRACT
from 20 adult women without AML revealed that nearly
all studied individuals harbored somatic mutations fre-
quently observed in myeloid malignancies. The detected
hematopoietic clones were often stable over the ten years
between blood collections and did not demonstrate posi-
tive selection or clonal expansion, regardless of the gene
mutated. It is important to note that clonal mutations at a
lower frequency than 0.02 VAF are currently not regarded
as CHIP, and their clinical significance is even less well
understood. The two aforementioned studies of pre-diag-
nosis CHIP observed associations of increased AML risk
for persons with clones ≥0.005 or ≥0.01 VAF over a shorter
follow-up period.4,5 The present investigation examined
whether detection of lower-VAF clones or specific muta-
tions are associated with future risk of AML in a nested
case-control sample (35 cases, 70 controls) from the
Nurses’ Health Study (NHS) and Health Professionals
Follow-up Study (HPFS) cohorts with up to 22 years of fol-
low up after sample collection.8,9 We also investigated
whether clonal evolution over ten years was associated
with long-term future risk of AML in 11 women in the
NHS with multiple pre-diagnosis samples.
Methods
Study population 
Details of the NHS and HPFS design and data collection and fol-
low-up methods are published elsewhere8,9 (see also Online
Supplementary Methods). Biennial questionnaire return rates have
been consistently high (>95% in the blood subcohorts described
below).
Blood subcohorts
The “blood subcohorts” comprise 32,826 women (NHS) who
provided a heparinized whole blood sample from 1989-1990,10 of
whom 18,743 provided a second whole blood sample from 2000-
2001,11 as well as 18,018 men (HPFS) who provided an EDTA
whole blood sample from 1993-1995. Participants provided writ-
ten informed consent. The present study protocol was approved
by the Institutional Review Boards of Brigham and Women’s
Hospital, Harvard TH Chan School of Public Health and
Washington University.
Case and control selection
The present study utilized a nested case-control design for
which the case definition included all blood subcohort participants
with confirmed diagnoses of AML (ICD-8=205.0) occurring after
blood draw. We matched two controls per case on cohort (sex),
race, birthdate (±1 year), and blood draw details (date ±1 year,
time ±4 hours, fasting status). For NHS cases with a second collec-
tion sample, we matched controls with a second sample using the
same criteria. These protocols selected 35 cases (16 NHS, 19 HPFS)
and 70 controls (32 NHS, 38 HPFS), including 11 matched sets
(NHS) with two samples (n=137 total samples after excluding four
with insufficient volume).
Clonal hematopoiesis of indeterminate potential 
determination and validation 
Sequencing libraries were prepared as previously described6
using the Illumina TruSight Myeloid Sequencing Panel for targeted
capture from 54 leukemia-associated genes (Online Supplementary
Methods and Online Supplementary  Table S1). Libraries were
sequenced on the Illumina HiSeq 3000 platform per manufacturer
specifications; with technical replicate libraries sequenced on dif-
ferent machine runs. ECS analysis of raw sequencing results was
performed as previously described,6 except that, to improve rare
SNV identification at potential “hot spot” loci, we re-called vari-
ants from the binomial error model after removing the variants
already identified until a subsequent iteration revealed no addi-
tional new variants. We reported single nucleotide variants (SNV)
and insertions and deletions (indels) identified in both technical
replicates for a given sample. To validate our ECS-based variant
calls, we performed droplet digital polymerase chain reaction
(ddPCR) for 61 variants.
Statistical analysis
We combined NHS and HPFS data to maximize statistical
power. We analyzed mutations detected in both technical repli-
cates for ≥4 participants and selected VAF thresholds (≥0.001,
≥0.005, ≥0.01, ≥0.02), in the first collection samples and in samples
from either collection. We used conditional logistic regression,
conditioning on matched sets, to calculate odds ratios (OR) and
95% confidence intervals (CI) for the relative risk of AML for a
given detected variant or VAF threshold. Sparse data precluded
evaluation of confounding by other AML risk factors3,12 or effect
modification. Exploratory and sensitivity analyses are detailed in
the Online Supplementary Methods. We utilized SAS version 9.3 for
statistical analyses and the ggplot2 and ppcor packages of R ver-
sion 3.3.313 for graphical descriptive analyses. Hypothesis tests
assumed a two-tailed a-error of 0.05.
Results
Study samples
Due to the matched design, the cases and controls had
similar distributions of sex, age at blood collection, and
interval from blood draw to case diagnosis or control
index date (Table 1). The median age of sample collection
was 61 years for the first collection and 70 years for the
second collection. The median age of AML diagnosis was
76 years (range: 53-87 years). More than 90% of cases and
controls had one year or more of follow up after blood
draw, and >88% of each group had follow-up intervals of
five or more years. All the women with repeat blood sam-
ples had at least one year of follow up after the second
blood collection (Table 1). All the participants selected into
the study sample had self-reported their race/ethnicity as
White.
Error-corrected sequencing results
During ECS library preparation, we generated an aver-
age of 60 million raw sequenced reads, yielding 3.9 million
ECS reads, per library, which translated into approximate-
ly 8,000x ECS read coverage of the target space. We iden-
tified 563 single nucleotide variants and 35 insertion/dele-
tion (indel) variants by ECS; this corresponded to detec-
tion of AML-associated mutations in 97% of all partici-
pants (598 mutations, 5.8/person), with an average of 7.4
(range: 1-14) per case and an average of 5.0 (range: 0-15)
per control (Online Supplementary Table S2). As expected,
due to the targeted enrichment sequencing scheme, these
mutations predominantly occurred in exonic regions
(Online Supplementary Figure S1A). Most detected muta-
tions were predicted to change the underlying amino acid
sequence in cases and controls (Online Supplementary Figure
S1B). Of the 252 clonal mutations detected in the cases,
we identified 144 non-synonymous SNV (57%), 40 stop
gain variants (16%), 22 intronic variants (9%), 18 indels
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(7%), 12 synonymous SNV (5%), 11 splice variants (4%),
4 UTR variants (2%), and one stop loss variant (<1%). Of
the 346 clonal mutations detected in the matched controls,
we identified 208 non-synonymous SNV (60%), 47
intronic variants (14%), 34 synonymous SNV (10%), 30
stop gain variants (9%), 13 indels (4%), 12 splice variants
(3%), and 2 UTR variants (<1%). As expected, C to T (G
to A) substitutions were by far the most common in both
cases and controls (Online Supplementary Figure S1C). 
Droplet digital polymerase chain reaction validation
Spearman correlation coefficients reflect a high corre-
spondence between ECS and ddPCR variant calls at both
blood collections (collection 1, r=0.97, P<0.0001; collec-
tion 2, r=0.95, P<0.0001) (Online Supplementary Table S3
and Online Supplementary Figure S2). 
Gene-specific mutations
As expected, the most frequently observed mutations
occurred in the epigenetic regulators DNMT3A and TET2,
although we observed mutations in most of the genes tar-
geted by the assay (Figure 1 and Online Supplementary
Figure S3). In cases, we observed 58 DNMT3A and 56
TET2 clonal variants, comprising 23% and 22% of the 252
clonal variants detected in cases, respectively. In controls,
we observed 128 DNMT3A and 57 TET2 clonal mutations,
comprising 37% and 16% of the 346 clonal mutations
detected in controls, respectively. Most mutations
occurred in exonic regions and were predominantly non-
synonymous and nonsense mutations (Online
Supplementary Figure S3). The observed exonic variants in
DNMT3A occurred predominantly in the functional
domains (Online Supplementary Figure 4A). The observed
exonic variants in TET2 occurred across the entire amino
acid sequence (Online Supplementary Figure 4B). No single
mutation in TET2was observed in more than two individ-
uals. 
Association of individual variants and clonal
hematopoiesis with acute myeloid leukemia risk
For the mutations that occurred in at least four individ-
uals, associations with AML were similar in magnitude
whether we classified mutation status according to the
first or according to either blood collection (Table 2). Thus,
for brevity, we focus herein on the findings based on
either blood collection. Detecting the DNMT3A R822H
variant at either time point was associated with a 14-fold
increased risk of AML (OR: 14.0, 95%CI: 1.7-113.8;
P=0.01).  Participants with either a DNMT3A R882H or
R882C variant (“R882H/C”) at either collection had a
more than 7-fold increased risk of AML relative to individ-
uals without either variant (OR: 7.3, 95%CI: 1.5-34.7;
P=0.01). For the DNMT3A W860R and ASXL1 E1183K
variants, the sparse counts prevented estimation of 95%CI
by the conditional logistic regression models (implying a
95%CI range from zero to infinity).  The JAK2 V617F vari-
A.L. Young et al.
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Table 1. Selected characteristics of study participants by case-control status.
                                                                                                         Cases (N=34)                                               Controls (N=69)
Sex (cohort), N (%)                                                                                                                                                                                              
Female (NHS)                                                                                                        15 (44.1)                                                                      31 (44.9)
Male (HPFS)                                                                                                           19 (55.9)                                                                      38 (55.1)
Age (years) at blood draw, median (range)                                                                                                                                                    
Collection 1                                                                                                            61 (48-70)                                                                   61 (48-71)
Collection 2a                                                                                                           70 (62-78)                                                                   70 (62-79)
Age (years) at case diagnosis date, median (range)b                                   76 (53-87)                                                                   75 (53-87)
Years, blood collection to case diagnosis                                                                                                                                                        
Collection 1,                                                                                                                                                                                                          
Mean (±SD)                                                                                                       14.2 (±6.1)                                                                 14.1 (±6.0)
N (%) by intervalc                                                                                                                                                                                               
<1                                                                                                                            2 (5.9)                                                                          6 (8.7)
1 to <5                                                                                                                    2 (5.9)                                                                          2 (2.9)
5 to <10                                                                                                                  2 (5.9)                                                                          4 (5.8)
10 to <15                                                                                                               9 (26.5)                                                                       18 (26.1)
15 to <20                                                                                                              15 (44.1)                                                                      31 (44.9)
≥20                                                                                                                         4 (11.8)                                                                        8 (11.6)
Collection 2,a                                                                                                                                                                                                         
Mean (±SD)                                                                                                      6.4 (±2.6)a                                                               6.3 (±2.8)a
N (%) by intervalc                                                                                                                                                                                               
<1                                                                                                                            0 (0.0)                                                                          0 (0.0)
1 to <5                                                                                                                   2 (16.7)                                                                        6 (26.1)
5 to <10                                                                                                                 8 (66.7)                                                                       13 (56.5)  
≥10                                                                                                                         2 (16.7)                                                                        4 (17.4)
N: number; AML: acute myeloid leukemia; HPFS: Health Professionals Follow-up Study; NHS: Nurses’ Health Study; SD: standard deviation. aSecond blood samples were available
for 11 cases and 21 controls in the NHS. bIn controls, defined as date of AML diagnosis for the matched case. cCase percentages do not sum to 100 due to rounding.
ant, which we observed only in men in the present study
sample, had a non-significant positive association with
future development of AML (Table 2). 
Individuals with clonal mutations detected at ≥0.01
(OR: 5.4, 95%CI: 1.8-16.6; P=0.003) or ≥0.02 VAF (OR:
5.6, 95%CI: 1.8-17.2; P=0.003) had a significantly
increased risk of AML compared to those without a muta-
tion detected at or above those thresholds (Table 2). The
association with AML risk for VAF lower than 0.01 was
unclear; for example, individuals with mutations at a VAF
of ≥0.005 at either blood collection had a 2.5-fold increase
in AML risk that was not statistically significant (OR: 2.5,
95%CI: 1.0-6.3; P=0.05). Further, nearly every case and
most controls had at least one clonal mutation at ≥0.001
VAF. Of interest, the ASXL1 E1183K variant noted above,
which we observed in five women (4 cases, 1 control) and
for which an association with AML risk could not be well
quantified due to sparse counts, occurred at VAF between
0.001 and 0.002.
Sensitivity analyses that omitted records for the cases
and controls with less than one year of follow up after
blood collection did not materially change the main find-
ings. One omitted case and two omitted controls were
positive for DNMT3A R882H/C, whereas the remaining
omitted case and four omitted controls were negative for
that variant. Even after omitting these participants, detect-
ing the DNMT3A R882H/C variant at one or both blood
collections remained a statistically significant risk factor
for AML (OR: 14.0, 95%CI: 1.7-113.8; P=0.01), as did
detecting any mutation with a VAF ≥0.01 (OR: 5.1,
95%CI: 1.6-15.9; P=0.005) or ≥0.02 (OR: 5.3, 95%CI: 1.7-
16.4; P=0.004).
In the exploratory analyses restricted to AML cases, we
did not observe marked differences in time to AML diag-
nosis by DNMT3A R882H/C mutation status (detected vs.
not detected) or by detection of any mutation at VAF of
≥0.005, ≥0.01 or ≥0.02 at either blood draw (Online
Supplementary Figure S5A-D). 
Clonal stability 
We examined clonal evolution of mutations over time in
11 matched sets of women (NHS) with samples banked
approximately ten years apart (Figure 2A). The VAF of
mutations detected in these cases at blood collection one
(median: 0.0021; range: 0.0003-0.0782) and blood collec-
tion two (median: 0.0037; range: 0.0006-0.2992) was very
similar to controls at collection one (median: 0.0017;
range: 0.0003-0.0731) and collection two (median: 0.0023;
range: 0.0003-0.2689). In the cases with two blood collec-
tions, 31 clonal mutations occurred only at the first blood
draw, 37 occurred only at the second blood draw, and 22
occurred at both time points (see Figure 2A; yellow data
points connected with a line). Of the latter 22 clonal muta-
tions, in the approximately ten years between the first and
second blood draw, five (23%) increased by >0.01 VAF,
none decreased by >0.01 VAF, and 17 (77%) were
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Figure 1. Distribution of exonic clonal mutations by gene in cases and controls.
Each bar represents the fraction of exonic mutations detected in each gene rel-
ative to the total number of exonic mutations detected in cases (n=215) or con-
trols (n=285).
unchanged. In controls with two blood collections, 27
clonal mutations occurred only at the first blood draw, 58
only at the second blood draw, and 29 at both time points
(Figure 2A; blue and red data points connected by lines).
Of the latter 29 clonal mutations, in the approximately ten
years between the first and second blood draw, five (17%)
increased by >0.01 VAF, none decreased by >0.01 VAF, and
24 (83%) were unchanged. In the 22 matched sets of men
(HPFS) with only one banked sample, we again observed
a similar VAF for clonal mutations detected in cases [medi-
an (range) VAF: 0.0020 (0.0002-0.3280)] and controls
[median (range) VAF: 0.0014 (0.0002-0.3513)] (Figure 2B). 
A.L. Young et al.
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Figure 2. Clonal mutations detected
in study participants. (A) Clonal
dynamics for women with two blood
samples collected approximately ten
years apart. Trios of one case and
two controls are shown in each
panel. The ages at first and second
collection are on the x-axis while the
variant allele fraction is on the y-axis.
Dots connected by a line represent
the same mutation seen in both
blood collections. Individual dots rep-
resent mutations only seen in a sin-
gle blood collection. (B) Clonal muta-
tions for individuals with only a single
blood collection. Trios of one
matched case and two controls are
shown in each panel with female
trios numbered <100 and male trios
numbered >100. The y-axis portrays
variant allele fraction and each dot
represents a mutation seen in the
respective individual.
A
B
In exploratory case-only analyses (see Online
Supplementary Methods), the VAF for the most abundant
clone observed at the first blood draw (i.e. the largest VAF
observed at collection one) did not correlate to the time to
diagnosis of AML (partial Spearman r = -0.11, P=0.55,
adjusted for age and sex) (Figure 3A). In the NHS cases
with a second collection blood sample, the maximum VAF
at the second time point and time to AML diagnosis was
not correlated (partial Spearman r=0.34, P=0.33, adjusted
for age) (Figure 3B). The largest change in VAF between
collections with time to AML diagnosis was also not cor-
related (partial Spearman r=0.30, P=0.39, adjusted for age)
(Figure 3C). 
Discussion 
In this study, we investigated associations of clonal
hematopoiesis with long-term risk of AML, leveraging
ECS-determined clonal variants and up to 22 years of fol-
low up after blood draw in 34 matched case-control sets
from the NHS and HPFS.  Surprisingly, we found no clear
differences in clonal mutation abundance, location or VAF
between cases and controls. As expected, DNMT3A and
TET2 were the genes with the most frequently detected
clonal mutations in both cases and controls,2,6,14 and over-
all, cases and controls showed abundant mutation across
the rest of the coding sequence. Few individual variants
occurred frequently enough for separate analysis of AML
risk, but among those occurring in at least four partici-
pants, DNMT3A R882H/C had a strong association with
AML risk. We also observed statistically significant associ-
ations with AML risk for individuals with any variant
with a VAF ≥0.01. Contrary to expectation, in the 11
matched sets with two banked blood samples, we did not
observe a signature of clonal evolution over time that dis-
tinguished cases from controls or predicted latency to
AML diagnosis in the cases.  
Two recent studies reported findings for clonal
hematopoiesis and future risk of AML.4,5 Briefly, both
studies observed an increased risk of AML for increasing
numbers of clonal mutations, higher VAF and detection or
number of mutations in known driver genes. Of note,
Abelson et al.5 observed an increased AML risk for individ-
uals with clones of VAF ≥0.005 detected by ECS, and
Desai et al.4 reported an increased risk of AML for women
with clones of VAF ≥0.01 detected by targeted deep
sequencing. We detected an increase in AML risk for per-
sons with clonal mutations at ≥0.01 VAF and those with
DNMT3A R882 mutations, and our observed effect esti-
mates had a similar magnitude and precision as those
reported by the previous studies. Other prior studies
reported that these mutations raise AML risk by 0.5-
1%/year.2,3 For mutations detected at VAF <0.01, our find-
ings were less clear due to limited statistical precision.
Additionally, in the subset of women with repeat blood
Clonal hematopoiesis and AML risk
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Table 2. Future risk of acute myeloid leukemia associated with individual variants and selected variant allele frequencies detected in pre-diag-
nosis blood samplesa in a pooled sample from the NHS and HPFS cohorts.
                                                                                                 Total testing positivea                          
Gene or VAF criterionb      Polymorphism               Major/minor allele             Cases           Controls              OR (95% CI)d                            P
                                                                                                                       (N=34)c          (N=69)c                                                                
                          First blood collection only
DNMT3A                                R882H or R882C                          C/T or G/A                             7                          3                        6.3 (1.3, 30.7)                                0.02
                                                    R882H only                                     C/T                                   6                          1                       12.0 (1.4, 99.7)                               0.02
                                                        W860R                                         A/G                                   0                          4                             0.0 (NC)                                       
ASXL1                                             E1183K                                        G/A                                   4                          1                         2.0x107(NC)                                   
JAK2                                                 V617F                                          G/T                                  4e                      1e                       8.0 (0.9, 71.6)                                0.06
Any VAF ≥0. 001                                                                                                                      33                        57                        2.3x107 (NC)                                   
Any VAF ≥0.005                                                                                                                        22                        31                        2.4 (1.0, 6.1)                                 0.06
Any VAF ≥0.01                                                                                                                          14                        17                        2.5 (0.9, 7.1)                                 0.07
Any VAF ≥0.02                                                                                                                          11                        10                        3.2 (1.1, 9.7)                                 0.04
                     First or second blood collectionf
DNMT3A                                R882H or R882C                          C/T or G/A                             8                          3                        7.3 (1.5, 34.7)                                0.01
                                                    R882H only                                     C/T                                   7                          1                      14.0 (1.7, 113.8)                             0.01
                                                        W860R                                         A/G                                   0                          5                             0.0 (NC)                                       
Any VAF ≥0.001                                                                                                                        34                        63                        1.7x107 (NC)                                   
Any VAF ≥0.005                                                                                                                        26                        39                        2.5 (1.0, 6.3)                                 0.05
Any VAF ≥0.01                                                                                                                          20                        19                       5.4 (1.8, 16.6)                               0.003
Any VAF ≥0.02                                                                                                                          17                        13                       5.6 (1.8, 17.2)                               0.003
AML: acute myeloid leukemia; CI: confidence interval; HPFS: Health Professionals Follow-up Study; NHS: Nurses’ Health Study; OR: odds ratio; NC: not calculable due to zero or
sparse cell counts; VAF: variant allele fraction. aA participant was considered positive for a given mutation if both technical repeats for the same collection time tested positive;
otherwise the participant was classified as negative for that mutation and collection time. bPolymorphism-specific analyses were limited to individual polymorphisms detected
in at least four individuals in a given blood collection; VAF cut-off point variables were defined according to all mutations detected in a given person in both technical repeats
for the given blood collection. cThe pooled N for cases includes 15 women in the NHS and 19 men in the HPFS; the pooled N for the controls includes 31 women in the NHS
and 38 men in the HPFS.  A second blood sample was available for 11 cases and 21 controls from the NHS. dThe OR, 95%CI and P-values were calculated using conditional
logistic regression, conditioning on the matched sets [matched on cohort (e.g. sex), age, and date of blood draw]. eJAK2 V617F was detected only in men. fPolymorphism-specific
results were tabulated only for the polymorphisms with additional positive case or control samples in NHS blood collection 2.
samples, we did not observe clonal expansion over ten
years and found no evidence among the AML cases that
the most abundant clone at either an early or late time
point, or the largest difference in VAF between time points
for any clone, correlated with time to AML onset.
Similarly, neither of the previous studies observed differ-
ences in clonal expansion in individuals with serial sam-
ples who did or did not eventually develop AML.4,5
However, Desai et al.4 observed striking differences in time
to AML diagnosis for individuals with any baseline muta-
tion and noted that the degree of diminished latency var-
ied by mutation and clonal complexity. With our smaller
sample size, we lacked resolution to perform as detailed
an analysis of mutational complexity of clonal
hematopoiesis, or of temporal changes, as the prior larger
studies. Nonetheless, our findings extended, by several
years, the pre-diagnosis period during which detection of
clonal hematopoiesis could be informative for identifying
individuals at an increased risk for AML. 
Notably, we observed relatively similar VAF of clonal
hematopoietic mutations in cases and controls, whereas
the Abelson et al. and Desai et al. studies4,5 reported more
striking differences in the overall VAF and mutational
complexity of CHIP in cases and controls. The explanation
for these discrepancies is not immediately clear, although
differences in methodology for control matching or differ-
ing average lengths of follow up across the three studies
may have contributed. In the present study, we did not
have sufficient sample size to compare mutational profiles
of cases versus controls within more proximal and more
distal follow-up periods, but it is plausible that contrasts in
clonal hematopoiesis profiles between individuals who do
and do not progress may deepen as diagnosis of malignan-
cy approaches. 
Our observation of an increased risk of AML in individ-
uals with variants at the DNMT3A R882 locus is unsur-
prising, given the prevalence of DNMT3A R882 hotspot
mutations in AML,15 but also highlights that different
mutations in the same gene do not convey the same risk
and should not be viewed as equivalent a priori. Of inter-
est, one of the few other individual variants that occurred
relatively frequently in the present study sample,
DNMT3A W860R, occurred more commonly in controls
than in cases. This raises the question as to whether the
aggregation of variable mutations across any single gene is
appropriate to evaluate true AML risk. Larger studies with
sufficient statistical power to examine individual muta-
tions at varying VAF (and, perhaps, combinations of indi-
vidual variants) may prove informative for further refining
the interpretation of clonal hematopoiesis for stratifying
risk of AML.
The strengths of this research include studying two
large, well-characterized population-based cohorts with
many years of follow up after blood collection. We
matched cases and controls carefully on potential con-
founding variables including age, ethnicity, sex, and
date(s) of blood collection and utilized conditional logistic
regression for efficient control of confounding by those
variables in the analysis. Further, for a subset of women in
the NHS, we explored and compared temporal changes in
clonal hematopoiesis over an approximately 10-year inter-
val in those who did or did not subsequently develop
AML. We conducted ECS assays and ddPCR validation in
a blinded manner and observed strong reproducibility of
variant calls across orthogonal platforms, affirming the
A.L. Young et al.
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Figure 3. Comparison between the largest variant allele fraction (VAF) or
largest change in VAF per individual with acute myeloid leukemia (AML) (x-axis)
and the time to AML diagnosis (y-axis). (A) The VAF for the most common muta-
tion observed in a first or only blood collection sample is plotted relative to the
time to AML diagnosis from the date of first or only blood collection. (B) The VAF
for the most common mutation observed in a second blood collection sample is
plotted relative to the time to AML diagnosis from the date of second blood col-
lection. (C) The time from the second blood draw to AML diagnosis in partici-
pants with two blood samples, based on the largest observed increase in VAF
between the first and second blood collections (regardless of the corresponding
variant).
A
B
C
credibility of variants detected at very low VAF.  
The most notable limitations of the study relate to sam-
ple size and statistical precision, as previously noted. We
had insufficient statistical power for concurrent interroga-
tion of multiple mutations and for more than exploratory
analysis of clone size and time to AML diagnosis.
Likewise, we could not control for potential confounding
variables (other than matching factors), such as body mass
index or history of cigarette smoking,10,12 or stratify by
those variables or by follow-up time. Additionally, myelo-
proliferative neoplasms and myelodysplastic syndrome
were not routinely reported in the NHS and HPFS, so we
were unable to identify which participants had clonal
hematopoiesis attributable to one of these pre-malignant
disorders. Further, we did not have access to AML diag-
nostic samples for the cases in this study, making it impos-
sible to determine which, if any, clonal hematopoietic
mutations detected prior to diagnosis appeared in the
founding AML clone. The study was limited technically
by the sequencing panel, which targeted 54 genes recur-
rently mutated in AML. Future studies should expand the
panel to target the entire exome or at least include addi-
tional genes that have been observed in CHIP, such as
PPM1D,1 to more fully characterize the spectrum of muta-
tions in clonal hematopoiesis. However, any increase in
panel size must be balanced with the cost of sequencing,
which is higher for ECS compared to conventional NGS.
Lastly, ECS, while precise, cannot co-localize mutations
within the same cell. Future single-cell sequencing studies
would provide further insights into the evolution of pre-
leukemic clones and potentially improve screening for risk
of developing AML.  
In summary, we demonstrated that detection of AML-
associated variants at VAF as low as 0.01 is associated
with long-term risk of AML in concordance with other
recent reports. Additionally, our study has extended by
several years the period of follow up over which this
increased risk applies and provided evidence that even
individual variants in known driver genes may be associ-
ated with AML risk, suggesting that not all clonal somatic
variants have equivalent associations with AML. The col-
lective data from this and previous reports underscore
that, while clonal hematopoiesis is associated with a
markedly increased long-term risk of AML, the vast major-
ity of individuals with detectable clonal hematopoiesis
will not develop AML. Likewise, further detailed investi-
gation is needed to incorporate detection of clonal
hematopoiesis into AML-risk assessment for healthy indi-
viduals. Such studies will require considerably larger pop-
ulations, ideally with serial samples and sufficient sample
size to analyze multiple features of clonal hematopoiesis
(including individual variants, gene-level mutational pro-
files and temporal evolution of variant clones) as well as
additional genetic, epigenetic and environmental factors
that may influence the stepwise progression of healthy
cells to leukemic clones. Future work will also need to
incorporate single cell sequencing technology to identify,
which rare clonal mutations occur in the same cells and
tease out the sequence of mutation acquisition driving the
transformation from clonal hematopoiesis to AML.
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